Vetenskaplig data

FÖRFATTARE TITEL DATUM ÄMNE
Sax PE et al. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials Maj 2023 BVY TREATMENT DURING 5Y
Jespersen NA et al. The burden of non-communicable diseases and mortality in people living with HIV (PLHIV) in the pre-, early- and late-HAART era Juli 2021 BURDEN OF COMORBIDTIES IN PWH
Maggiolo F et al. Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/ Emtricitabine/Tenofovir Alafenamide 3 Nov 2022 RWD FORGIVENESS OF BVY
Esser S et al. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts 17 Nov 2023 RWD OF BVY
Gaur AH et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial 21 Juli 2021 CHILDREN AND ADOLESCENT DATA BVY
Maggiolo F et al. Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial 9 Mars 2021 AGED ≥ 65 DATA BVY
Daar ES et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial Juli 2018 SWITCH REGISTRATIONAL TRIAL BVY
Molina JM et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial 17 Juni 2018 SWITCH REGISTRATIONAL TRIAL BVY
Sax PE et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial Aug 2017 NAIVE REGISTRATIONAL TRIAL BVY
Gallant J et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial Nov 2017 NAIVE REGISTRATIONAL TRIAL BVY
Segal-Maurer S et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection Maj 2022 LENACAPAVIR STUDY
Ogbuagu O et al. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial Augusti 2023 LENACAPAVIR STUDY
Kontakta oss

Kontakta våra sälj- och medicinska team

Har du frågor om våra läkemedel eller produkter? Kontakta oss.

Kontakta oss Kontakta våra medicinska team

SE-COR-0031; SEP 2024